# Antimicrobial Prophylaxis per CD4 Counts 

Rachel Pellegrino

---

| 0               | 1                                              | 2                                                                             | 3                                                                                          | 4                                                                            |
|-----------------|------------------------------------------------|-------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| CD4 counts      | Opportunistic Infection                        | Indication for Prophylaxis                                                    | Medication                                                                                 | Special Notes                                                                |
| <200 cells/mm3 | Pneumocystis Pneumonia (PJP)                   | CD4 < 200, or CD4 < 14%, or CD4 200-250 w/ delayed init. ART & poor f/u     | TMP-SMX: 1 DS daily (qd), or TMP-SMX: 1SS qd TMP-SMX: 1 DS TIW                             | If intolerant of TMP-SMX: dapsone\*, or pentamidine, or atovaquone           |
| <200 cells/mm3 | Toxoplasma gondii encephalitis                 | Toxoplasma IgG + and CD4 < 100                                               | TMP-SMX 1 DS tab daily                                                                     | Alternative regimens: Dapsone, or Atovaquone (all regimens effect. for PJP ) |
| <200 cells/mm3 | Mycobacterium avium- intracellulare (MAC, MAI) | Only if not on fully suppressive ART and active disseminated MAC is ruled out | - Azithromycin 1200 mg weekly, or -Clarithromycin 500 mg BID, or - Rifabutin 300 mg daily | NOT indicated for those initiating ART                                       |

| Infection                                          | Screening Indication                                                                                                                                                                                               | Intervention                                                                       |
|----------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| Hepatitis A Virus (HAV)                            | Non-immune w/ â†‘ risk for HAV infection (MSM, IVDU) or chronic liver disease                                                                                                                                        | HAV vaccine                                                                        |
| Hepatitis B Virus (HBV)                            | Pts w/o chronic HBV or non-immune                                                                                                                                                                                  | HBV vaccine. Ideally admin. before CD4 < 350                                      |
| Human Papilloma virus (HPV)                        | Age 13-45                                                                                                                                                                                                          | HPV vaccine series                                                                 |
| Influenza A and B Virus                            | All patients                                                                                                                                                                                                       | Yearly inactivated influenza vaccine                                               |
| Latent Mycobacterium tuberculosis infection (LTBI) | -Pts with positive screening test for LTBI w/ no evidence of active disease. -Pts w/ known exposure                                                                                                                | (INH 300mg + pyridoxine 25-50mg) PO daily for 9 months                             |
| Streptococcus pneumoniae                           | All patients                                                                                                                                                                                                       | PCV13 and PPV23 (order and timing depends on previous vaccination history and CD4) |
| Syphilis                                           | All pts exposed to sex partner with syphilis diagnosis                                                                                                                                                             | Screening for syphilis and gonorrhea/chlamydia with treatment if indicated.        |
| Varicella Zoster Virus (VZV)                       | Pre-exposure: CD4 >200, no previous vaccine.Shingrix (recombinant vaccine) is not live virus, only Zostavax (live virus) is contraindicated for CD4 <200). Post-exposure: Close contact, particularly if CD4 <200 | Pre-exposure: Consider vaccination Post-exposure: Varicella-zoster immune globulin |
